title: TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control.
abstract: OBJECTIVE
  To describe patient perceptions regarding their experience and to report findings in a retrospective analysis of glycemic control in a cohort of patients who used the V-Go, a mechanical, 24-hour disposable, subcutaneous continuous insulin delivery device that delivers a preset basal infusion rate and on-demand insulin.
  
  
  METHODS
  Patients used the V-Go and answered telephone surveys about their perception of device use. Corresponding clinical data were retrospectively collected before V-Go initiation, after 12 weeks of use, at the end of treatment, and 12 weeks after discontinuation. Analyses were performed with nonparametric statistical tests.
  
  
  RESULTS
  Twenty-three patients participated. Mean values of the following characteristics were documented: patient age, 61 years; body mass index, 30 kg/m2; diabetes duration, 16 years; duration of insulin therapy, 7 years; average duration of V-Go use, 194 days; and mean total daily insulin dose, 50 U at baseline, 46 U while on V-Go, and 51 U after stopping V-Go treatment. Mean patient rating of the overall experience was 9.1 at 12 weeks on a scale from 1 to 10 (10 being most positive). Mean hemoglobin A1c value decreased from baseline (8.8% to 7.6%; [P = .005]) while using the V-Go, and it increased to 8.2% after treatment. Fasting plasma glucose trended from 205 mg/dL at baseline to 135 mg/dL while using V-Go and increased to 164 mg/dL after V-Go was stopped. Weight was essentially unchanged. No differences in hypoglycemic events were found; site reactions were minor.
  
  
  CONCLUSIONS
  Glycemic control improved when patients were switched to the V-Go for insulin delivery, and it deteriorated when the V-Go was discontinued.
authors.affiliation: North Jersey Endocrine Consultants, Denville, New Jersey, USA.
authors.forename: Cheryl R
authors.initials: CR
authors.lastname: Rosenfeld
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Bohannon
authors.forename: Bruce
authors.initials: B
authors.lastname: Bode
authors.forename: Adam S
authors.initials: AS
authors.lastname: Kelman
authors.forename: Shari N
authors.initials: SN
authors.lastname: Mintz
authors.forename: Alan B
authors.initials: AB
authors.lastname: Schorr
authors.forename: Marc I
authors.initials: MI
authors.lastname: Sandberg
authors.forename: Sridhar
authors.initials: S
authors.lastname: Nambi
authors.forename: Sumon K
authors.initials: SK
authors.lastname: Agarwala
authors.forename: Steven B
authors.initials: SB
authors.lastname: Leichter
authors.forename: Bart
authors.initials: B
authors.lastname: Larrabee
authors.forename: Lei
authors.initials: L
authors.lastname: Shi
authors.forename: Poul
authors.initials: P
authors.lastname: Strange
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin